董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Suren Ajjarapu | -- | Director | 52 | 未披露 | 未持股 | 2023-01-12 |
| Chirinjeev Kathuria | 男 | Founder, Executive Chairman, Director | 58 | 未披露 | 未持股 | 2023-01-12 |
| Elizabeth Ng | 女 | Chief Executive Officer and Director | 66 | 681.16万美元 | 未持股 | 2023-01-12 |
| Jonathan Kurtis | -- | Director | 55 | 未披露 | 未持股 | 2023-01-12 |
| Jack A. Elias | 男 | Director | 71 | 未披露 | 未持股 | 2023-01-12 |
| Martin D. Angle | 男 | Director | 72 | 未披露 | 未持股 | 2023-01-12 |
| Michelle Berrey | 女 | Director | 56 | 未披露 | 未持股 | 2023-01-12 |
| Jerome Ringo | 男 | Director | 67 | 未披露 | 未持股 | 2023-01-12 |
| William Owens | 男 | Director | 72 | 未披露 | 未持股 | 2023-01-12 |
| Michael L. Peterson | 男 | Director | 60 | 未披露 | 未持股 | 2023-01-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chirinjeev Kathuria | 男 | Founder, Executive Chairman, Director | 58 | 未披露 | 未持股 | 2023-01-12 |
| Elizabeth Ng | 女 | Chief Executive Officer and Director | 66 | 681.16万美元 | 未持股 | 2023-01-12 |
| Gurinder Kalra | 男 | Chief Financial Officer | 57 | 113.53万美元 | 未持股 | 2023-01-12 |
| Inderjote Kathuria | 男 | Chief Strategy Officer | 56 | 113.53万美元 | 未持股 | 2023-01-12 |
| Daniel Behr | 男 | Executive Vice President and Head of External Innovation and Academic Partnerships | 64 | 340.58万美元 | 未持股 | 2023-01-12 |
| Robert Sweeney | 男 | Chief Accounting Officer | 57 | 未披露 | 未持股 | 2023-01-12 |
董事简历
中英对照 | 中文 | 英文- Suren Ajjarapu
-
自招股说明书构成部分的注册声明生效之日起，Suren Ajjarapu一直担任我们的董事之一。Ajjarapu自2010年7月起担任TrxadeGroup，Inc.（NASDAQ:MEDS，特拉华州一家公司及其前身公司）董事长、首席执行官和秘书。自2018年3月以来，Ajjarapu先生一直担任Kano Energy Corp.的董事会执行主席，该公司参与了美国可再生天然气站点的开发。Ajjarapu先生是Sansur Renewable Energy，Inc.的创始人，并于2009年3月至2012年12月担任首席执行官兼董事会主席，Sansur Renewable Energy，Inc.是一家参与开发美国中西部风电站点的公司。Ajjarapu先生还从2006年1月到2009年3月担任Aemetis，Inc.（一家生物燃料公司，纳斯达克股票代码:AMTX）的创始人、总裁兼董事，以及International Biofuels（Aemetis，Inc.的一家子公司）的创始人、董事长兼首席执行官。Ajjarapu先生是Global Information Technology，Inc.的联合创始人，首席运营官兼董事，Global Information Technology，Inc.是一家IT外包和系统设计公司，总部位于佛罗里达州坦帕，在印度拥有主要业务。Ajjarapu先生毕业于南达科他州立大学，获得环境工程硕士学位，并毕业于南佛罗里达大学，获得国际金融和管理专业的工商管理硕士学位。Ajjarapu先生还是哈佛大学风险资本和私募股权计划的毕业生。
暂无英文简介 - 自招股说明书构成部分的注册声明生效之日起，Suren Ajjarapu一直担任我们的董事之一。Ajjarapu自2010年7月起担任TrxadeGroup，Inc.（NASDAQ:MEDS，特拉华州一家公司及其前身公司）董事长、首席执行官和秘书。自2018年3月以来，Ajjarapu先生一直担任Kano Energy Corp.的董事会执行主席，该公司参与了美国可再生天然气站点的开发。Ajjarapu先生是Sansur Renewable Energy，Inc.的创始人，并于2009年3月至2012年12月担任首席执行官兼董事会主席，Sansur Renewable Energy，Inc.是一家参与开发美国中西部风电站点的公司。Ajjarapu先生还从2006年1月到2009年3月担任Aemetis，Inc.（一家生物燃料公司，纳斯达克股票代码:AMTX）的创始人、总裁兼董事，以及International Biofuels（Aemetis，Inc.的一家子公司）的创始人、董事长兼首席执行官。Ajjarapu先生是Global Information Technology，Inc.的联合创始人，首席运营官兼董事，Global Information Technology，Inc.是一家IT外包和系统设计公司，总部位于佛罗里达州坦帕，在印度拥有主要业务。Ajjarapu先生毕业于南达科他州立大学，获得环境工程硕士学位，并毕业于南佛罗里达大学，获得国际金融和管理专业的工商管理硕士学位。Ajjarapu先生还是哈佛大学风险资本和私募股权计划的毕业生。
- 暂无英文简介
- Chirinjeev Kathuria
-
自2021年6月业务合并结束以来，Chirinjeev Kathuria一直担任Uphealth，Inc.董事会成员，此前还担任Uphealth，Inc.董事会联席主席至2022年6月。Kathuria博士是一位印度裔美国投资者、商人和慈善家。在2019年11月重组UpHealth服务公司后，他于2020年10月与他人共同创立了UpHealth控股公司。在业务合并完成之前，他曾担任UpHealth控股公司和UpHealth服务公司的董事会主席。Kathuria博士于2019年1月与他人共同创立了Ocean Biomedical，并自成立以来一直担任该公司的董事会主席。Ocean Biomedical是一家生物技术公司，与领先的科学家和研究机构合作，以加速将新发现转化为突破性药物。Kathuria博士还于2020年3月与他人共同创立了AIRO集团，并担任该集团董事会主席，自成立以来一直担任这一职务。AIRO集团为国防和商业市场的下一代航空电子设备、有人驾驶和无人驾驶以及多模式运输提供端到端解决方案。此外，Kathuria博士于2009年2月与他人共同创立并担任New Generation Power的董事长，并于2003年3月创立并担任American Teleradiology NightHawks，Inc.的董事。美国Teleradiology NightHawks，Inc.与NightHawk Radiology Holdings，Inc.合并，合并后的公司于2006年10月在纳斯达克上市。Kathuria博士于1998年3月至2000年3月担任X-Stream网络公司的董事，该公司是一家互联网服务提供商，后来被出售给Liberty Surf Group S.A.，随后在巴黎证券交易所上市。Kathuria博士还参与了空间探索，并于1999年1月成为MirCorp的创始董事，这是第一家私人发射和资助载人航天计划的商业公司。Kathuria博士在伊利诺伊州竞选美国联邦参议员，成为美国历史上第一位竞选美国联邦参议员的印裔美国人，其中包括最终的获胜者奥巴马总统。Kathuria博士在布朗大学获得理学学士学位和医学博士学位，在斯坦福大学获得工商管理硕士学位。
Chirinjeev Kathuria has served Executive Chairman since inception in 2020. Dr. Kathuria is an Indian American investor, binessperson, and philanthropist. He is co founder and serves on the board of directors of UpHealth, Inc. (OTC: UPH), a digital health company founded in 2020. Dr. Kathuria also co founded Ocean Biomedical, Inc. (Nasdaq: OCEA), a biopharmaceutical company, and serves as the executive chairman of its board of directors, a position he has held since its inception in 2019. In addition, Dr. Kathuria co founded New Generation Por, an energy company, in February 2009 and American Teleradiology NightHawks, Inc., a telemedicine company, in March 2003. American Teleradiology NightHawks, Inc. merged with NightHawk Radiology Holdings, Inc. and the combined company nt public on Nasdaq in October 2006. From March 1998 to March 2000, Dr. Kathuria served as a director of The X Stream Networks Inc., an internet service provider, that was sold to Liberty Surf Group S.A. and subsequently nt public on the Paris Stock Exchange. Dr. Kathuria has also been involved in space exploration and, in January 1999, became the founding director of MirCorp, the first commercial company to privately launch and fund manned space programs. Dr. Kathuria received a Bachelor of Science and Doctor of Medicine from Brown University and a Master of Biness Administration from Stanford University. - 自2021年6月业务合并结束以来，Chirinjeev Kathuria一直担任Uphealth，Inc.董事会成员，此前还担任Uphealth，Inc.董事会联席主席至2022年6月。Kathuria博士是一位印度裔美国投资者、商人和慈善家。在2019年11月重组UpHealth服务公司后，他于2020年10月与他人共同创立了UpHealth控股公司。在业务合并完成之前，他曾担任UpHealth控股公司和UpHealth服务公司的董事会主席。Kathuria博士于2019年1月与他人共同创立了Ocean Biomedical，并自成立以来一直担任该公司的董事会主席。Ocean Biomedical是一家生物技术公司，与领先的科学家和研究机构合作，以加速将新发现转化为突破性药物。Kathuria博士还于2020年3月与他人共同创立了AIRO集团，并担任该集团董事会主席，自成立以来一直担任这一职务。AIRO集团为国防和商业市场的下一代航空电子设备、有人驾驶和无人驾驶以及多模式运输提供端到端解决方案。此外，Kathuria博士于2009年2月与他人共同创立并担任New Generation Power的董事长，并于2003年3月创立并担任American Teleradiology NightHawks，Inc.的董事。美国Teleradiology NightHawks，Inc.与NightHawk Radiology Holdings，Inc.合并，合并后的公司于2006年10月在纳斯达克上市。Kathuria博士于1998年3月至2000年3月担任X-Stream网络公司的董事，该公司是一家互联网服务提供商，后来被出售给Liberty Surf Group S.A.，随后在巴黎证券交易所上市。Kathuria博士还参与了空间探索，并于1999年1月成为MirCorp的创始董事，这是第一家私人发射和资助载人航天计划的商业公司。Kathuria博士在伊利诺伊州竞选美国联邦参议员，成为美国历史上第一位竞选美国联邦参议员的印裔美国人，其中包括最终的获胜者奥巴马总统。Kathuria博士在布朗大学获得理学学士学位和医学博士学位，在斯坦福大学获得工商管理硕士学位。
- Chirinjeev Kathuria has served Executive Chairman since inception in 2020. Dr. Kathuria is an Indian American investor, binessperson, and philanthropist. He is co founder and serves on the board of directors of UpHealth, Inc. (OTC: UPH), a digital health company founded in 2020. Dr. Kathuria also co founded Ocean Biomedical, Inc. (Nasdaq: OCEA), a biopharmaceutical company, and serves as the executive chairman of its board of directors, a position he has held since its inception in 2019. In addition, Dr. Kathuria co founded New Generation Por, an energy company, in February 2009 and American Teleradiology NightHawks, Inc., a telemedicine company, in March 2003. American Teleradiology NightHawks, Inc. merged with NightHawk Radiology Holdings, Inc. and the combined company nt public on Nasdaq in October 2006. From March 1998 to March 2000, Dr. Kathuria served as a director of The X Stream Networks Inc., an internet service provider, that was sold to Liberty Surf Group S.A. and subsequently nt public on the Paris Stock Exchange. Dr. Kathuria has also been involved in space exploration and, in January 1999, became the founding director of MirCorp, the first commercial company to privately launch and fund manned space programs. Dr. Kathuria received a Bachelor of Science and Doctor of Medicine from Brown University and a Master of Biness Administration from Stanford University.
- Elizabeth Ng
-
Elizabeth Ng，自Ocean Biomedical成立以来一直担任其首席执行官和董事会成员。Ng女士自2018年起担任Bioelectric Devices Inc.的副总裁/战略与业务发展主管。此前，她曾于2010年至2017年在BioMarin制药公司担任投资组合战略高级总监，在此之前，她曾在默克公司担任战略发展集团总监，并在吉利德科学公司担任商业/投资组合战略总监。吴女士拥有麻省理工学院的物理学学士学位和斯坦福大学的工商管理硕士学位。
Elizabeth Ng served as the Chief Executive Officer of Ocean Biomedical, Inc., a public biopharmaceutical company, from January 2019 to October 2024 and currently serves as a member of the Ocean Biomedical, Inc.'s board of directors since January 2019. Ms. Ng previoly served as Vice President/Head of Strategy and Biness Development at Bioelectric Devices Inc. starting in 2018. Previoly, she served as Senior Director of Portfolio Strategy at BioMarin Pharmaceutical Inc. from 2010 to 2017 and prior to that, as Director Strategy Development Group at Merck & Co. Inc., and Director of Commercial/Portfolio Strategy at Gilead Sciences. Ms. Ng holds a B.S. in Physics from the Massachetts Institute of Technology and an M.B.A. from Stanford University. - Elizabeth Ng，自Ocean Biomedical成立以来一直担任其首席执行官和董事会成员。Ng女士自2018年起担任Bioelectric Devices Inc.的副总裁/战略与业务发展主管。此前，她曾于2010年至2017年在BioMarin制药公司担任投资组合战略高级总监，在此之前，她曾在默克公司担任战略发展集团总监，并在吉利德科学公司担任商业/投资组合战略总监。吴女士拥有麻省理工学院的物理学学士学位和斯坦福大学的工商管理硕士学位。
- Elizabeth Ng served as the Chief Executive Officer of Ocean Biomedical, Inc., a public biopharmaceutical company, from January 2019 to October 2024 and currently serves as a member of the Ocean Biomedical, Inc.'s board of directors since January 2019. Ms. Ng previoly served as Vice President/Head of Strategy and Biness Development at Bioelectric Devices Inc. starting in 2018. Previoly, she served as Senior Director of Portfolio Strategy at BioMarin Pharmaceutical Inc. from 2010 to 2017 and prior to that, as Director Strategy Development Group at Merck & Co. Inc., and Director of Commercial/Portfolio Strategy at Gilead Sciences. Ms. Ng holds a B.S. in Physics from the Massachetts Institute of Technology and an M.B.A. from Stanford University.
- Jonathan Kurtis
-
Jonathan Kurtis，自2021年3月起在Ocean Biomedical董事会任职，并担任科学顾问委员会成员。Kurtis博士目前是布朗大学医学院病理学和实验室医学系主任，布朗大学医学博士项目主任。Kurtis博士自2020年3月起担任Elkurt制药公司董事会成员。Kurtis博士拥有布朗大学的学士、博士和医学博士学位，并在病理学和临床病理学方面获得董事会认证。
Jonathan Kurtis,has served on Ocean Biomedical's board of directors since March 2021 and serves as a member of its scientific advisory board. Dr. Kurtis is currently Chair, Department of Pathology & Lab Medicine, Brown University Medical School and Director, MD/PhD Program, Brown University. Dr. Kurtis has served as a member of the board of directors of Elkurt Pharmaceuticals since March 2020. Dr. Kurtis holds a B.A., Ph.D. and M.D. from Brown University and is board certified in pathology and clinical pathology. - Jonathan Kurtis，自2021年3月起在Ocean Biomedical董事会任职，并担任科学顾问委员会成员。Kurtis博士目前是布朗大学医学院病理学和实验室医学系主任，布朗大学医学博士项目主任。Kurtis博士自2020年3月起担任Elkurt制药公司董事会成员。Kurtis博士拥有布朗大学的学士、博士和医学博士学位，并在病理学和临床病理学方面获得董事会认证。
- Jonathan Kurtis,has served on Ocean Biomedical's board of directors since March 2021 and serves as a member of its scientific advisory board. Dr. Kurtis is currently Chair, Department of Pathology & Lab Medicine, Brown University Medical School and Director, MD/PhD Program, Brown University. Dr. Kurtis has served as a member of the board of directors of Elkurt Pharmaceuticals since March 2020. Dr. Kurtis holds a B.A., Ph.D. and M.D. from Brown University and is board certified in pathology and clinical pathology.
- Jack A. Elias
-
Jack A. Elias，自2022年8月起在Ocean Biomedical董事会任职。自2022年3月起，Elias博士担任布朗大学生物和医学名誉院长，并担任Warren Alpert转化科学教授。他还担任分子生物学、细胞生物学和生物化学教授，自2014年1月起担任该职位，并担任布朗大学分子微生物学和免疫学教授和医学教授，自2013年9月起担任该职位。从2017年4月到2022年3月，Elias博士是布朗大学卫生事务部的高级副总裁。2013年9月至2022年3月，Elias博士还担任布朗大学生物学和医学系主任和Frank L. Day生物学教授。Elias博士在宾夕法尼亚大学获得了学士和医学博士学位。
Jack A. Elias,has served on Ocean Biomedical's board of directors since August 2022. Since March 2022, Dr. Elias has served as Emeritus Dean, Biology and Medicine and as Warren Alpert Professor of Translational Sciences at Brown University. He is also a Professor of Molecular Biology Cell Biology and Biochemistry, a position he has held since January 2014, and a Professor of Molecular Microbiology and Immunology and Professor of Medicine at Brown University, positions he has held since September 2013. From April 2017 to March 2022, Dr. Elias was the Senior Vice President for Health Affairs at Brown University. Dr. Elias also served as Dean, Biology and Medicine and as Frank L. Day Professor of Biology at Brown University from September 2013 to March 2022. Dr. Elias received his B.A. and M.D. from the University of Pennsylvania. - Jack A. Elias，自2022年8月起在Ocean Biomedical董事会任职。自2022年3月起，Elias博士担任布朗大学生物和医学名誉院长，并担任Warren Alpert转化科学教授。他还担任分子生物学、细胞生物学和生物化学教授，自2014年1月起担任该职位，并担任布朗大学分子微生物学和免疫学教授和医学教授，自2013年9月起担任该职位。从2017年4月到2022年3月，Elias博士是布朗大学卫生事务部的高级副总裁。2013年9月至2022年3月，Elias博士还担任布朗大学生物学和医学系主任和Frank L. Day生物学教授。Elias博士在宾夕法尼亚大学获得了学士和医学博士学位。
- Jack A. Elias,has served on Ocean Biomedical's board of directors since August 2022. Since March 2022, Dr. Elias has served as Emeritus Dean, Biology and Medicine and as Warren Alpert Professor of Translational Sciences at Brown University. He is also a Professor of Molecular Biology Cell Biology and Biochemistry, a position he has held since January 2014, and a Professor of Molecular Microbiology and Immunology and Professor of Medicine at Brown University, positions he has held since September 2013. From April 2017 to March 2022, Dr. Elias was the Senior Vice President for Health Affairs at Brown University. Dr. Elias also served as Dean, Biology and Medicine and as Frank L. Day Professor of Biology at Brown University from September 2013 to March 2022. Dr. Elias received his B.A. and M.D. from the University of Pennsylvania.
- Martin D. Angle
-
Martin D. Angle，自2021年3月起在Ocean Biomedical董事会任职。自2019年3月以来，安格尔先生担任Spire Healthcare集团副主席兼高级独立董事，该集团是英国最大的私立医院供应商之一，在英格兰、威尔士和苏格兰拥有39家医院和8家诊所。在Spire，Angle先生也是提名委员会主席以及审计和风险委员会和薪酬委员会的成员。自2019年11月起，安格尔先生担任埃克塞特大学社会科学与国际研究学院荣誉教授。自2018年7月起，Angle先生还担任Gulf Keystone Petroleum plc副主席兼高级独立董事。自2018年7月起，Angle先生还担任AIRO Group，Inc.及其附属公司的顾问。Angle先生曾于2008年12月至2018年12月任职于Pennon Group plc、2007年1月至2016年5月任职于Savills Plc、2006年12月至2015年12月任职于National Exhibition Group、2007年1月至2015年5月任职于Severstal、2006年11月至2009年11月任职于Dubai International Capital、2009年8月至2016年5月任职于Shuaa Capital。他曾于1997年2月至2000年12月在富时100指数公司TI集团担任集团财务总监。在其早期的高管生涯中，安格尔曾在摩根士丹利的华保公司担任过多个投资银行领域的高级职位。
Martin D. Angle,has served on Ocean Biomedical's board of directors since March 2021. Since March 2019, Mr. Angle has served as Deputy Chairman and Senior Independent Director of Spire Healthcare Group, one of the UK's largest private hospital providers with 39 hospitals and 8 clinics across England, Wales and Scotland. At Spire, Mr. Angle is also chair of the Nomination Committee and a member of the Audit and Risk Committee and Remuneration Committee. Since November 2019, MR. Angle has served as an Hon.Professor at the University of Exeter attached to the College of Social Sciences and International Studies. Mr. Angle has also served as Deputy Chairman and Senior Independent Director of Gulf Keystone Petroleum plc since July 2018. Mr. Angle has also served as an advisor to AIRO Group, Inc. and its affiliates since July 2018. Mr. Angle has previously served on the boards of Pennon Group plc from December 2008 to December 2018, Savills Plc from January 2007 to May 2016, National Exhibition Group from December 2006 to December 2015, Severstal from January 2007 to May 2015, Dubai International Capital from November 2006 to November 2009, and Shuaa Capital from August 2009 to May 2016. He previously served as Group Finance Director of TI Group, a FTSE 100 company with worldwide engineering activities from February 1997 to December 2000. In his earlier executive career, Mr. Angle held a number of senior positions in investment banking with S.G. Warburg & Co, Morgan Stanley and Kleinwort Benson. Mr. Angle has also served as Operating Managing Director at Terra Firma Capital Partners from March 2001 to January 2006, where he held a number of senior roles in its portfolio companies including Le Meridien Hotel Group (Executive Deputy Chairman and acting Chairman) and the Waste Recycling Group (Executive Chairman), then one of the leading UK waste management businesses. Mr. Angle is a chartered accountant and he holds a B.S. in Physics from University of Warwick. - Martin D. Angle，自2021年3月起在Ocean Biomedical董事会任职。自2019年3月以来，安格尔先生担任Spire Healthcare集团副主席兼高级独立董事，该集团是英国最大的私立医院供应商之一，在英格兰、威尔士和苏格兰拥有39家医院和8家诊所。在Spire，Angle先生也是提名委员会主席以及审计和风险委员会和薪酬委员会的成员。自2019年11月起，安格尔先生担任埃克塞特大学社会科学与国际研究学院荣誉教授。自2018年7月起，Angle先生还担任Gulf Keystone Petroleum plc副主席兼高级独立董事。自2018年7月起，Angle先生还担任AIRO Group，Inc.及其附属公司的顾问。Angle先生曾于2008年12月至2018年12月任职于Pennon Group plc、2007年1月至2016年5月任职于Savills Plc、2006年12月至2015年12月任职于National Exhibition Group、2007年1月至2015年5月任职于Severstal、2006年11月至2009年11月任职于Dubai International Capital、2009年8月至2016年5月任职于Shuaa Capital。他曾于1997年2月至2000年12月在富时100指数公司TI集团担任集团财务总监。在其早期的高管生涯中，安格尔曾在摩根士丹利的华保公司担任过多个投资银行领域的高级职位。
- Martin D. Angle,has served on Ocean Biomedical's board of directors since March 2021. Since March 2019, Mr. Angle has served as Deputy Chairman and Senior Independent Director of Spire Healthcare Group, one of the UK's largest private hospital providers with 39 hospitals and 8 clinics across England, Wales and Scotland. At Spire, Mr. Angle is also chair of the Nomination Committee and a member of the Audit and Risk Committee and Remuneration Committee. Since November 2019, MR. Angle has served as an Hon.Professor at the University of Exeter attached to the College of Social Sciences and International Studies. Mr. Angle has also served as Deputy Chairman and Senior Independent Director of Gulf Keystone Petroleum plc since July 2018. Mr. Angle has also served as an advisor to AIRO Group, Inc. and its affiliates since July 2018. Mr. Angle has previously served on the boards of Pennon Group plc from December 2008 to December 2018, Savills Plc from January 2007 to May 2016, National Exhibition Group from December 2006 to December 2015, Severstal from January 2007 to May 2015, Dubai International Capital from November 2006 to November 2009, and Shuaa Capital from August 2009 to May 2016. He previously served as Group Finance Director of TI Group, a FTSE 100 company with worldwide engineering activities from February 1997 to December 2000. In his earlier executive career, Mr. Angle held a number of senior positions in investment banking with S.G. Warburg & Co, Morgan Stanley and Kleinwort Benson. Mr. Angle has also served as Operating Managing Director at Terra Firma Capital Partners from March 2001 to January 2006, where he held a number of senior roles in its portfolio companies including Le Meridien Hotel Group (Executive Deputy Chairman and acting Chairman) and the Waste Recycling Group (Executive Chairman), then one of the leading UK waste management businesses. Mr. Angle is a chartered accountant and he holds a B.S. in Physics from University of Warwick.
- Michelle Berrey
-
Michelle Berrey自2021年3月起在Aesther Healthcare Acquisition Corp.董事会任职。Berrey博士是Intercept Pharmaceuticals, Inc.的研发总裁兼首席医疗官，该公司是一家生物制药公司，专门从事治疗非病毒性肝病的新型疗法的开发和商业化，她自2021年6月起担任这些职务。在加入Intercept制药之前，Berrey博士在2012年11月加入Chimerix担任首席医疗官后，于2014年4月至2019年2月担任Chimerix总裁兼首席执行官。Berrey博士于2007年1月至2012年1月被Gilead Sciences收购时担任Pharmasset的首席医疗官。在此之前，Berrey博士于1999年8月至2007年1月在GlaxoSmithKline plc领导抗病毒产品的临床开发。她是华盛顿大学传染病医学高级研究员，并在北卡罗来纳大学教堂山分校完成了实习和内科实习。Berrey博士目前在北卡罗来纳州生物技术中心的董事会和执行委员会任职，并在Viiv/GSK的科学顾问委员会任职。Berrey博士拥有乔治亚医学院的医学博士学位和埃默里大学罗林斯公共卫生学院的公共卫生硕士学位。
Michelle Berrey,has served on Aesther Healthcare Acquisition Corp. board of directors since March 2021. Dr. Berrey is the President of Research and Development and Chief Medical Officer of Intercept Pharmaceuticals, Inc., a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat non-viral liver diseases, and she has served in those roles since June 2021. Prior to joining Intercept Pharmaceuticals, Dr. Berrey served as President and Chief Executive Officer of Chimerix from April 2014 to February 2019, after joining Chimerix Inc. as Chief Medical Officer in November 2012. Dr. Berrey served as Chief Medical Officer for Pharmasset, Inc. from January 2007 to January 2012 when it was acquired by Gilead Sciences, Inc. Prior to that, Dr. Berrey led the clinical development of antiviral products at GlaxoSmithKline plc from August 1999 to January 2007. She was a Senior Fellow in Infectious Disease Medicine at the University of Washington and completed her internship and residency in internal medicine at University of North Carolina, Chapel Hill. Dr. Berrey currently serves on the Board and Executive Committee for the North Carolina Biotechnology Center and is on the Scientific Advisory Board for ViiV/GSK. Dr. Berrey holds an M.D. from the Medical College of Georgia and an M.P.H. from the Emory University Rollins School of Public Health. - Michelle Berrey自2021年3月起在Aesther Healthcare Acquisition Corp.董事会任职。Berrey博士是Intercept Pharmaceuticals, Inc.的研发总裁兼首席医疗官，该公司是一家生物制药公司，专门从事治疗非病毒性肝病的新型疗法的开发和商业化，她自2021年6月起担任这些职务。在加入Intercept制药之前，Berrey博士在2012年11月加入Chimerix担任首席医疗官后，于2014年4月至2019年2月担任Chimerix总裁兼首席执行官。Berrey博士于2007年1月至2012年1月被Gilead Sciences收购时担任Pharmasset的首席医疗官。在此之前，Berrey博士于1999年8月至2007年1月在GlaxoSmithKline plc领导抗病毒产品的临床开发。她是华盛顿大学传染病医学高级研究员，并在北卡罗来纳大学教堂山分校完成了实习和内科实习。Berrey博士目前在北卡罗来纳州生物技术中心的董事会和执行委员会任职，并在Viiv/GSK的科学顾问委员会任职。Berrey博士拥有乔治亚医学院的医学博士学位和埃默里大学罗林斯公共卫生学院的公共卫生硕士学位。
- Michelle Berrey,has served on Aesther Healthcare Acquisition Corp. board of directors since March 2021. Dr. Berrey is the President of Research and Development and Chief Medical Officer of Intercept Pharmaceuticals, Inc., a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat non-viral liver diseases, and she has served in those roles since June 2021. Prior to joining Intercept Pharmaceuticals, Dr. Berrey served as President and Chief Executive Officer of Chimerix from April 2014 to February 2019, after joining Chimerix Inc. as Chief Medical Officer in November 2012. Dr. Berrey served as Chief Medical Officer for Pharmasset, Inc. from January 2007 to January 2012 when it was acquired by Gilead Sciences, Inc. Prior to that, Dr. Berrey led the clinical development of antiviral products at GlaxoSmithKline plc from August 1999 to January 2007. She was a Senior Fellow in Infectious Disease Medicine at the University of Washington and completed her internship and residency in internal medicine at University of North Carolina, Chapel Hill. Dr. Berrey currently serves on the Board and Executive Committee for the North Carolina Biotechnology Center and is on the Scientific Advisory Board for ViiV/GSK. Dr. Berrey holds an M.D. from the Medical College of Georgia and an M.P.H. from the Emory University Rollins School of Public Health.
- Jerome Ringo
-
杰罗姆·林戈，自2021年3月起担任Ocean Biomedical董事会成员。林戈先生是国际公认的气候变化问题思想领袖，领导了世界上两个最大的环境组织，即拥有500万成员的国家野生动物联合会和拥有1900万成员的阿波罗联盟，这是历史上最大的绿色工作联盟。自2021年11月起，Ringo先生担任Zoetic Global的Founder兼董事长，该公司专注于为非洲发展中国家提供能效和发电方面的突破性技术。自2017年7月起，他担任泛非议会贸易和投资亲善大使。林戈先生于2018年2月至2020年2月在环境保护基金董事会任职，并曾在多家Renewable能源公司担任执行董事和董事会成员。他拥有Lord's Place神学学院的荣誉博士学位。
Jerome Ringo,has served on Ocean Biomedical's board of directors since March, 2021. Mr. Ringo is an internationally recognized thought leader on climate change issues and has led two of the largest environmental organizations in the world, the 5-million-member National Wildlife Federation and the Apollo Alliance, a 19-million-member organization which was the largest coalition on green jobs in history. Since November 2021, Mr. Ringo has served as Founder and Chairman of Zoetic Global, a company focused on delivering breakthrough technologies in energy efficiency and generation for developing nations in Africa. Since July 2017, he has served as Goodwill Ambassador, Trade and Investment, for the Pan-African Parliament. Mr. Ringo served on the Environmental Defense Fund's board of directors from February 2018 to February 2020, and he has served as executive and board member at various renewable energy companies. He holds an Honorary Doctorate from the Lord's Place School of Theology. - 杰罗姆·林戈，自2021年3月起担任Ocean Biomedical董事会成员。林戈先生是国际公认的气候变化问题思想领袖，领导了世界上两个最大的环境组织，即拥有500万成员的国家野生动物联合会和拥有1900万成员的阿波罗联盟，这是历史上最大的绿色工作联盟。自2021年11月起，Ringo先生担任Zoetic Global的Founder兼董事长，该公司专注于为非洲发展中国家提供能效和发电方面的突破性技术。自2017年7月起，他担任泛非议会贸易和投资亲善大使。林戈先生于2018年2月至2020年2月在环境保护基金董事会任职，并曾在多家Renewable能源公司担任执行董事和董事会成员。他拥有Lord's Place神学学院的荣誉博士学位。
- Jerome Ringo,has served on Ocean Biomedical's board of directors since March, 2021. Mr. Ringo is an internationally recognized thought leader on climate change issues and has led two of the largest environmental organizations in the world, the 5-million-member National Wildlife Federation and the Apollo Alliance, a 19-million-member organization which was the largest coalition on green jobs in history. Since November 2021, Mr. Ringo has served as Founder and Chairman of Zoetic Global, a company focused on delivering breakthrough technologies in energy efficiency and generation for developing nations in Africa. Since July 2017, he has served as Goodwill Ambassador, Trade and Investment, for the Pan-African Parliament. Mr. Ringo served on the Environmental Defense Fund's board of directors from February 2018 to February 2020, and he has served as executive and board member at various renewable energy companies. He holds an Honorary Doctorate from the Lord's Place School of Theology.
- William Owens
-
William Owens， 自2010年1月起，他一直担任董事。1999年至2007年，他担任科罗拉多州的州长；1995年至1999年，担任科罗拉多州的财政部长。自2007年以来，他曾就职于董事会及主要能源服务（一家油田服务公司）的审计委员会；自2010年起，就职董事会和比尔巴雷特公司薪酬及企业管治委员会；自2011年起，就职董事会和联邦信号公司（一家工业产品公司）补偿及企业管治委员会。2008年至2013年，他还就职于Vision Logistics（一家私人运输公司）的董事会及审计委员会。他获得了奥斯汀州立大学科学学士学位和德克萨斯大学公共事务硕士学位。
William Owens has served as a director since January 2010. Mr. Owens served as Governor of Colorado from 1999 to 2007 and as Colorado State Treasurer from 1995 to 1999. Since January 2016 Mr. Owens has served as a Senior Director with the law firm Greenberg Traurig. Mr. Owens has served on the board of directors, compensation and corporate governance committees of Bill Barrett Corporation since 2010; and on the board of directors, compensation and corporate governance committees of Federal Signal Corporation, an industrial products company, since 2011. In addition, Mr. Owens has served as a member of the supervisory board of Credit Bank of Moscow, a medium-sized privately owned bank operating in Moscow, Russia and the Moscow region, since 2012 as chairman of its supervisory board since 2013 and as a member of its compensation, corporate governance and nominations committee and of its strategy and capital markets committee since 2013. Mr. Owens also served on the board of directors and audit committee of Key Energy Services, an oilfield services company, from 2007 to 2016; and on the board of directors and audit committee of Vision Logistics, a private transportation company, from 2008 to 2013. Mr. Owens earned a Bachelor of Science degree from Stephen F. Austin State University and a Master’s degree in public affairs from the University of Texas. - William Owens， 自2010年1月起，他一直担任董事。1999年至2007年，他担任科罗拉多州的州长；1995年至1999年，担任科罗拉多州的财政部长。自2007年以来，他曾就职于董事会及主要能源服务（一家油田服务公司）的审计委员会；自2010年起，就职董事会和比尔巴雷特公司薪酬及企业管治委员会；自2011年起，就职董事会和联邦信号公司（一家工业产品公司）补偿及企业管治委员会。2008年至2013年，他还就职于Vision Logistics（一家私人运输公司）的董事会及审计委员会。他获得了奥斯汀州立大学科学学士学位和德克萨斯大学公共事务硕士学位。
- William Owens has served as a director since January 2010. Mr. Owens served as Governor of Colorado from 1999 to 2007 and as Colorado State Treasurer from 1995 to 1999. Since January 2016 Mr. Owens has served as a Senior Director with the law firm Greenberg Traurig. Mr. Owens has served on the board of directors, compensation and corporate governance committees of Bill Barrett Corporation since 2010; and on the board of directors, compensation and corporate governance committees of Federal Signal Corporation, an industrial products company, since 2011. In addition, Mr. Owens has served as a member of the supervisory board of Credit Bank of Moscow, a medium-sized privately owned bank operating in Moscow, Russia and the Moscow region, since 2012 as chairman of its supervisory board since 2013 and as a member of its compensation, corporate governance and nominations committee and of its strategy and capital markets committee since 2013. Mr. Owens also served on the board of directors and audit committee of Key Energy Services, an oilfield services company, from 2007 to 2016; and on the board of directors and audit committee of Vision Logistics, a private transportation company, from 2008 to 2013. Mr. Owens earned a Bachelor of Science degree from Stephen F. Austin State University and a Master’s degree in public affairs from the University of Texas.
- Michael L. Peterson
-
Michael L. Peterson，自2023年10月起担任Trio Petroleum Corp.首席执行官，自2022年7月起担任董事。他自2022年3月起担任Lafayette Energy Corporation的首席执行官，自2024年1月起担任Danam Health， Inc.（一家私营公司）的董事，自2021年1月起担任Integrated Wellness Acquisition Corp.（纳斯达克股票代码：WEL）的董事和Indonesia Energy Corporation（纽约证券交易所股票代码：INDO）的董事。自2016年8月以来，Peterson先生还担任TrxAde Group， Inc.（纳斯达克股票代码：MEDS）董事会的独立董事，这是一家总部位于佛罗里达州的基于网络的制药市场平台。在特殊目的收购公司的董事职位方面，他目前担任OceanTech Acquisitions I Corp（纳斯达克股票代码：OTEC）的董事（自2023年3月以来），Semper Paratus acquisition Corp（纳斯达克股票代码：LGST）的董事（自2023年5月以来），Powerup acquisition Corp（纳斯达克股票代码：PWUP）的董事（自2023年8月以来），在De-Spac的最后阶段都是SPAC。自2020年12月以来，他一直担任Nevo Motors， Inc.（一家将低碳排放卡车商业化的公司）的首席执行官。从2011年到2018年，Peterson先生担任PEDEVCO Corp.（纽约证券交易所美国股票代码：PED）的多个执行官职位，PEDEVCO Corp.是一家上市公司，主要从事美国石油和天然气页岩的收购、勘探、开发和生产。这些职位包括首席执行官、总裁、首席财务官和执行副总裁。从2006年到2012年，他曾担任Aemetis， Inc.（前身为AE biofuel Inc.）的多个高管职位，这是一家总部位于加州库比蒂诺的全球先进生物燃料和可再生商品化学品公司。这些职位包括临时总裁、董事和执行副总裁。从2008年12月到2012年7月，Peterson先生还担任Nevo Energy， Inc.（前身为Solargen Energy， Inc.）的董事长兼首席执行官，这是一家总部位于加州库比蒂诺的公用事业规模太阳能农场开发商，他帮助成立，目前作为Nevo Motors， Inc.运营。从2005年到2006年，Peterson先生担任American Institutional Partners的管理合伙人，这是一家总部位于Salt Lake City的风险投资基金。从2000年到2004年，他担任Merrill Lynch的第一副总裁，在那里他帮助建立了一个新的私人客户服务部门，专门与高净值投资者合作。从1989年9月到2000年1月，Peterson先生受雇于Goldman Sachs & Co.担任各种职位和角色，包括担任副总裁，负责一个专业团队，为超过70亿美元的资产提供建议和管理。自2018年从Pedevco退休以来，他一直担任the Church of Jesus Christ of Latter-day Saints台北台湾宣教会会长。他持有Marriott 管理学院的工商管理硕士学位，以及Brigham Young University的统计和计算机科学学士学位。
Michael L. Peterson has agreed to serve as a member of board of directors, to chair compensation committee, and to serve as a member of audit committee. Since January 2021, Mr. Peterson has served as a director of Indonesia Energy Corporation Limited (NYSE American: INDO). Mr. Peterson commenced serving as President, Chief Executive Officer and as a director of Lafayette Energy Corp. in April 2022. Mr. Peterson has also served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL), a special purpose acquisition company, since December 2022, served as a director of Oceantech Acquisitions I Corp. (NASDAQ: OTAC), a special purpose acquisition company, since March 2023, and served as a director of Integrated llness Acquisition Corp (OTC: LNF), a special purpose acquisition company, since February 2024. Mr. Peterson served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (OTC: OCEA)), a special purpose acquisition company, from June 2021 until the completion of its initial biness combination in February 2023. He served as a director of the post combination company Ocean Biomedical, Inc. (OTC: OCEA) until his voluntary resignation on July 31, 2025.Mr. Peterson formerly served as Interim President and CEO (from June 2009 to December 2011) and as director (from May 2008 to December 2011) of Pacific Energy Development, as a director (from May 2006 to July 2012) of Aemetis, Inc. (formerly AE Biofuels Inc.), a Cupertino, California based global advanced biofuels and renewable commodity chemicals company (NASDAQ: AMTX), and as Chairman and Chief Executive Officer of Nevo Energy, Inc. (NEVE) (formerly Solargen Energy, Inc.), a Cupertino, California based developer of utility scale solar farms which he helped form in December 2008 (from December 2008 to July 2012). From 2005 to 2006, Mr. Peterson served as a managing partner of American Institutional Partners, a venture investment fund based in Salt Lake City. From 2000 to 2004, he served as a First Vice President at Merrill Lynch, where he helped establish a new private client services division to work exclively with high net worth investors. From September 1989 to January 2000, Mr. Peterson was employed by Goldman Sachs & Co. in a variety of positions and roles, including as a Vice President. Mr. Peterson received his MBA at the Marriott School of Management and a BS in statistics/computer science from Brigham Young University. - Michael L. Peterson，自2023年10月起担任Trio Petroleum Corp.首席执行官，自2022年7月起担任董事。他自2022年3月起担任Lafayette Energy Corporation的首席执行官，自2024年1月起担任Danam Health， Inc.（一家私营公司）的董事，自2021年1月起担任Integrated Wellness Acquisition Corp.（纳斯达克股票代码：WEL）的董事和Indonesia Energy Corporation（纽约证券交易所股票代码：INDO）的董事。自2016年8月以来，Peterson先生还担任TrxAde Group， Inc.（纳斯达克股票代码：MEDS）董事会的独立董事，这是一家总部位于佛罗里达州的基于网络的制药市场平台。在特殊目的收购公司的董事职位方面，他目前担任OceanTech Acquisitions I Corp（纳斯达克股票代码：OTEC）的董事（自2023年3月以来），Semper Paratus acquisition Corp（纳斯达克股票代码：LGST）的董事（自2023年5月以来），Powerup acquisition Corp（纳斯达克股票代码：PWUP）的董事（自2023年8月以来），在De-Spac的最后阶段都是SPAC。自2020年12月以来，他一直担任Nevo Motors， Inc.（一家将低碳排放卡车商业化的公司）的首席执行官。从2011年到2018年，Peterson先生担任PEDEVCO Corp.（纽约证券交易所美国股票代码：PED）的多个执行官职位，PEDEVCO Corp.是一家上市公司，主要从事美国石油和天然气页岩的收购、勘探、开发和生产。这些职位包括首席执行官、总裁、首席财务官和执行副总裁。从2006年到2012年，他曾担任Aemetis， Inc.（前身为AE biofuel Inc.）的多个高管职位，这是一家总部位于加州库比蒂诺的全球先进生物燃料和可再生商品化学品公司。这些职位包括临时总裁、董事和执行副总裁。从2008年12月到2012年7月，Peterson先生还担任Nevo Energy， Inc.（前身为Solargen Energy， Inc.）的董事长兼首席执行官，这是一家总部位于加州库比蒂诺的公用事业规模太阳能农场开发商，他帮助成立，目前作为Nevo Motors， Inc.运营。从2005年到2006年，Peterson先生担任American Institutional Partners的管理合伙人，这是一家总部位于Salt Lake City的风险投资基金。从2000年到2004年，他担任Merrill Lynch的第一副总裁，在那里他帮助建立了一个新的私人客户服务部门，专门与高净值投资者合作。从1989年9月到2000年1月，Peterson先生受雇于Goldman Sachs & Co.担任各种职位和角色，包括担任副总裁，负责一个专业团队，为超过70亿美元的资产提供建议和管理。自2018年从Pedevco退休以来，他一直担任the Church of Jesus Christ of Latter-day Saints台北台湾宣教会会长。他持有Marriott 管理学院的工商管理硕士学位，以及Brigham Young University的统计和计算机科学学士学位。
- Michael L. Peterson has agreed to serve as a member of board of directors, to chair compensation committee, and to serve as a member of audit committee. Since January 2021, Mr. Peterson has served as a director of Indonesia Energy Corporation Limited (NYSE American: INDO). Mr. Peterson commenced serving as President, Chief Executive Officer and as a director of Lafayette Energy Corp. in April 2022. Mr. Peterson has also served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL), a special purpose acquisition company, since December 2022, served as a director of Oceantech Acquisitions I Corp. (NASDAQ: OTAC), a special purpose acquisition company, since March 2023, and served as a director of Integrated llness Acquisition Corp (OTC: LNF), a special purpose acquisition company, since February 2024. Mr. Peterson served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (OTC: OCEA)), a special purpose acquisition company, from June 2021 until the completion of its initial biness combination in February 2023. He served as a director of the post combination company Ocean Biomedical, Inc. (OTC: OCEA) until his voluntary resignation on July 31, 2025.Mr. Peterson formerly served as Interim President and CEO (from June 2009 to December 2011) and as director (from May 2008 to December 2011) of Pacific Energy Development, as a director (from May 2006 to July 2012) of Aemetis, Inc. (formerly AE Biofuels Inc.), a Cupertino, California based global advanced biofuels and renewable commodity chemicals company (NASDAQ: AMTX), and as Chairman and Chief Executive Officer of Nevo Energy, Inc. (NEVE) (formerly Solargen Energy, Inc.), a Cupertino, California based developer of utility scale solar farms which he helped form in December 2008 (from December 2008 to July 2012). From 2005 to 2006, Mr. Peterson served as a managing partner of American Institutional Partners, a venture investment fund based in Salt Lake City. From 2000 to 2004, he served as a First Vice President at Merrill Lynch, where he helped establish a new private client services division to work exclively with high net worth investors. From September 1989 to January 2000, Mr. Peterson was employed by Goldman Sachs & Co. in a variety of positions and roles, including as a Vice President. Mr. Peterson received his MBA at the Marriott School of Management and a BS in statistics/computer science from Brigham Young University.
高管简历
中英对照 | 中文 | 英文- Chirinjeev Kathuria
自2021年6月业务合并结束以来，Chirinjeev Kathuria一直担任Uphealth，Inc.董事会成员，此前还担任Uphealth，Inc.董事会联席主席至2022年6月。Kathuria博士是一位印度裔美国投资者、商人和慈善家。在2019年11月重组UpHealth服务公司后，他于2020年10月与他人共同创立了UpHealth控股公司。在业务合并完成之前，他曾担任UpHealth控股公司和UpHealth服务公司的董事会主席。Kathuria博士于2019年1月与他人共同创立了Ocean Biomedical，并自成立以来一直担任该公司的董事会主席。Ocean Biomedical是一家生物技术公司，与领先的科学家和研究机构合作，以加速将新发现转化为突破性药物。Kathuria博士还于2020年3月与他人共同创立了AIRO集团，并担任该集团董事会主席，自成立以来一直担任这一职务。AIRO集团为国防和商业市场的下一代航空电子设备、有人驾驶和无人驾驶以及多模式运输提供端到端解决方案。此外，Kathuria博士于2009年2月与他人共同创立并担任New Generation Power的董事长，并于2003年3月创立并担任American Teleradiology NightHawks，Inc.的董事。美国Teleradiology NightHawks，Inc.与NightHawk Radiology Holdings，Inc.合并，合并后的公司于2006年10月在纳斯达克上市。Kathuria博士于1998年3月至2000年3月担任X-Stream网络公司的董事，该公司是一家互联网服务提供商，后来被出售给Liberty Surf Group S.A.，随后在巴黎证券交易所上市。Kathuria博士还参与了空间探索，并于1999年1月成为MirCorp的创始董事，这是第一家私人发射和资助载人航天计划的商业公司。Kathuria博士在伊利诺伊州竞选美国联邦参议员，成为美国历史上第一位竞选美国联邦参议员的印裔美国人，其中包括最终的获胜者奥巴马总统。Kathuria博士在布朗大学获得理学学士学位和医学博士学位，在斯坦福大学获得工商管理硕士学位。
Chirinjeev Kathuria has served Executive Chairman since inception in 2020. Dr. Kathuria is an Indian American investor, binessperson, and philanthropist. He is co founder and serves on the board of directors of UpHealth, Inc. (OTC: UPH), a digital health company founded in 2020. Dr. Kathuria also co founded Ocean Biomedical, Inc. (Nasdaq: OCEA), a biopharmaceutical company, and serves as the executive chairman of its board of directors, a position he has held since its inception in 2019. In addition, Dr. Kathuria co founded New Generation Por, an energy company, in February 2009 and American Teleradiology NightHawks, Inc., a telemedicine company, in March 2003. American Teleradiology NightHawks, Inc. merged with NightHawk Radiology Holdings, Inc. and the combined company nt public on Nasdaq in October 2006. From March 1998 to March 2000, Dr. Kathuria served as a director of The X Stream Networks Inc., an internet service provider, that was sold to Liberty Surf Group S.A. and subsequently nt public on the Paris Stock Exchange. Dr. Kathuria has also been involved in space exploration and, in January 1999, became the founding director of MirCorp, the first commercial company to privately launch and fund manned space programs. Dr. Kathuria received a Bachelor of Science and Doctor of Medicine from Brown University and a Master of Biness Administration from Stanford University.- 自2021年6月业务合并结束以来，Chirinjeev Kathuria一直担任Uphealth，Inc.董事会成员，此前还担任Uphealth，Inc.董事会联席主席至2022年6月。Kathuria博士是一位印度裔美国投资者、商人和慈善家。在2019年11月重组UpHealth服务公司后，他于2020年10月与他人共同创立了UpHealth控股公司。在业务合并完成之前，他曾担任UpHealth控股公司和UpHealth服务公司的董事会主席。Kathuria博士于2019年1月与他人共同创立了Ocean Biomedical，并自成立以来一直担任该公司的董事会主席。Ocean Biomedical是一家生物技术公司，与领先的科学家和研究机构合作，以加速将新发现转化为突破性药物。Kathuria博士还于2020年3月与他人共同创立了AIRO集团，并担任该集团董事会主席，自成立以来一直担任这一职务。AIRO集团为国防和商业市场的下一代航空电子设备、有人驾驶和无人驾驶以及多模式运输提供端到端解决方案。此外，Kathuria博士于2009年2月与他人共同创立并担任New Generation Power的董事长，并于2003年3月创立并担任American Teleradiology NightHawks，Inc.的董事。美国Teleradiology NightHawks，Inc.与NightHawk Radiology Holdings，Inc.合并，合并后的公司于2006年10月在纳斯达克上市。Kathuria博士于1998年3月至2000年3月担任X-Stream网络公司的董事，该公司是一家互联网服务提供商，后来被出售给Liberty Surf Group S.A.，随后在巴黎证券交易所上市。Kathuria博士还参与了空间探索，并于1999年1月成为MirCorp的创始董事，这是第一家私人发射和资助载人航天计划的商业公司。Kathuria博士在伊利诺伊州竞选美国联邦参议员，成为美国历史上第一位竞选美国联邦参议员的印裔美国人，其中包括最终的获胜者奥巴马总统。Kathuria博士在布朗大学获得理学学士学位和医学博士学位，在斯坦福大学获得工商管理硕士学位。
- Chirinjeev Kathuria has served Executive Chairman since inception in 2020. Dr. Kathuria is an Indian American investor, binessperson, and philanthropist. He is co founder and serves on the board of directors of UpHealth, Inc. (OTC: UPH), a digital health company founded in 2020. Dr. Kathuria also co founded Ocean Biomedical, Inc. (Nasdaq: OCEA), a biopharmaceutical company, and serves as the executive chairman of its board of directors, a position he has held since its inception in 2019. In addition, Dr. Kathuria co founded New Generation Por, an energy company, in February 2009 and American Teleradiology NightHawks, Inc., a telemedicine company, in March 2003. American Teleradiology NightHawks, Inc. merged with NightHawk Radiology Holdings, Inc. and the combined company nt public on Nasdaq in October 2006. From March 1998 to March 2000, Dr. Kathuria served as a director of The X Stream Networks Inc., an internet service provider, that was sold to Liberty Surf Group S.A. and subsequently nt public on the Paris Stock Exchange. Dr. Kathuria has also been involved in space exploration and, in January 1999, became the founding director of MirCorp, the first commercial company to privately launch and fund manned space programs. Dr. Kathuria received a Bachelor of Science and Doctor of Medicine from Brown University and a Master of Biness Administration from Stanford University.
- Elizabeth Ng
Elizabeth Ng，自Ocean Biomedical成立以来一直担任其首席执行官和董事会成员。Ng女士自2018年起担任Bioelectric Devices Inc.的副总裁/战略与业务发展主管。此前，她曾于2010年至2017年在BioMarin制药公司担任投资组合战略高级总监，在此之前，她曾在默克公司担任战略发展集团总监，并在吉利德科学公司担任商业/投资组合战略总监。吴女士拥有麻省理工学院的物理学学士学位和斯坦福大学的工商管理硕士学位。
Elizabeth Ng served as the Chief Executive Officer of Ocean Biomedical, Inc., a public biopharmaceutical company, from January 2019 to October 2024 and currently serves as a member of the Ocean Biomedical, Inc.'s board of directors since January 2019. Ms. Ng previoly served as Vice President/Head of Strategy and Biness Development at Bioelectric Devices Inc. starting in 2018. Previoly, she served as Senior Director of Portfolio Strategy at BioMarin Pharmaceutical Inc. from 2010 to 2017 and prior to that, as Director Strategy Development Group at Merck & Co. Inc., and Director of Commercial/Portfolio Strategy at Gilead Sciences. Ms. Ng holds a B.S. in Physics from the Massachetts Institute of Technology and an M.B.A. from Stanford University.- Elizabeth Ng，自Ocean Biomedical成立以来一直担任其首席执行官和董事会成员。Ng女士自2018年起担任Bioelectric Devices Inc.的副总裁/战略与业务发展主管。此前，她曾于2010年至2017年在BioMarin制药公司担任投资组合战略高级总监，在此之前，她曾在默克公司担任战略发展集团总监，并在吉利德科学公司担任商业/投资组合战略总监。吴女士拥有麻省理工学院的物理学学士学位和斯坦福大学的工商管理硕士学位。
- Elizabeth Ng served as the Chief Executive Officer of Ocean Biomedical, Inc., a public biopharmaceutical company, from January 2019 to October 2024 and currently serves as a member of the Ocean Biomedical, Inc.'s board of directors since January 2019. Ms. Ng previoly served as Vice President/Head of Strategy and Biness Development at Bioelectric Devices Inc. starting in 2018. Previoly, she served as Senior Director of Portfolio Strategy at BioMarin Pharmaceutical Inc. from 2010 to 2017 and prior to that, as Director Strategy Development Group at Merck & Co. Inc., and Director of Commercial/Portfolio Strategy at Gilead Sciences. Ms. Ng holds a B.S. in Physics from the Massachetts Institute of Technology and an M.B.A. from Stanford University.
- Gurinder Kalra
Gurinder Kalra自2021年1月起担任Ocean Biomedical的首席财务官。Kalra先生拥有超过25年的投资和投资研究经验。在加入Ocean Biomedical之前，他是贝尔斯登的高级董事总经理
Gurinder Kalra,has served as Ocean Biomedical's Chief Financial Officer since January 2021. Mr. Kalra has more than 25 years of investment and investment research experience. Prior to joining Ocean Biomedical, he was a Senior Managing Director at Bear Stearns from 2000 to 2008. He was also a Partner at Crosslink LLC, an investment and consulting company he founded, from 2014 to 2020. Previously, Mr. Kalra was at Morgan Stanley from 1996 to 2000, rising to Executive Director. He initially got his start in investment research at CS First Boston (now part of Credit Suisse) from 1993 to 1996. He has been recognized in the All-America Institutional Investor Research Team, and multiple times in the All-Asia Institutional Investor Research Team as well as a number of other polls for investment research. Mr. Kalra holds a B.S. in Engineering and a B.A. in Business Economics from Brown University and an MBA from the Harvard Business School.- Gurinder Kalra自2021年1月起担任Ocean Biomedical的首席财务官。Kalra先生拥有超过25年的投资和投资研究经验。在加入Ocean Biomedical之前，他是贝尔斯登的高级董事总经理
- Gurinder Kalra,has served as Ocean Biomedical's Chief Financial Officer since January 2021. Mr. Kalra has more than 25 years of investment and investment research experience. Prior to joining Ocean Biomedical, he was a Senior Managing Director at Bear Stearns from 2000 to 2008. He was also a Partner at Crosslink LLC, an investment and consulting company he founded, from 2014 to 2020. Previously, Mr. Kalra was at Morgan Stanley from 1996 to 2000, rising to Executive Director. He initially got his start in investment research at CS First Boston (now part of Credit Suisse) from 1993 to 1996. He has been recognized in the All-America Institutional Investor Research Team, and multiple times in the All-Asia Institutional Investor Research Team as well as a number of other polls for investment research. Mr. Kalra holds a B.S. in Engineering and a B.A. in Business Economics from Brown University and an MBA from the Harvard Business School.
- Inderjote Kathuria
Inderjote Kathuria，于2020年1月至2021年1月担任Ocean Biomedical的财务主管兼首席财务官。自2021年1月起，他担任Ocean Biomedical的首席战略官。他是一位企业家和执业医师。他也是芝加哥大学的客座讲师。Kathuria博士拥有伊利诺伊大学的学士和医学博士学位以及芝加哥大学的工商管理硕士学位。
Inderjote Kathuria,served as Ocean Biomedical's Treasurer and Interim Chief Financial Officer from January 2020 until January 2021. Since January 2021, he has served as Ocean Biomedical's Chief Strategy Officer. He is an entrepreneur and licensed physician. He has also been a Guest Lecturer at the University of Chicago. Dr. Kathuria holds a B.A. and M.D. from the University of Illinois and an M.B.A from the University of Chicago.- Inderjote Kathuria，于2020年1月至2021年1月担任Ocean Biomedical的财务主管兼首席财务官。自2021年1月起，他担任Ocean Biomedical的首席战略官。他是一位企业家和执业医师。他也是芝加哥大学的客座讲师。Kathuria博士拥有伊利诺伊大学的学士和医学博士学位以及芝加哥大学的工商管理硕士学位。
- Inderjote Kathuria,served as Ocean Biomedical's Treasurer and Interim Chief Financial Officer from January 2020 until January 2021. Since January 2021, he has served as Ocean Biomedical's Chief Strategy Officer. He is an entrepreneur and licensed physician. He has also been a Guest Lecturer at the University of Chicago. Dr. Kathuria holds a B.A. and M.D. from the University of Illinois and an M.B.A from the University of Chicago.
- Daniel Behr
Daniel Behr，自2019年8月起担任Ocean Biomedical执行副总裁兼外部创新和学术合作伙伴关系主管。Behr先生曾于2017年7月至2019年7月担任布朗大学工业参与和商业风险办公室执行主任。Behr先生曾担任SLIPS技术公司的首席执行官。
Daniel Behr,has served as Ocean Biomedical's EVP and Head of External Innovation and Academic Partnerships since August 2019. Mr. Behr previously served as Executive Director of the Brown University Office of Industry Engagement and Commercial Venturing from July 2017 to July 2019. Mr. Behr served as the Chief Executive Officer of SLIPS Technologies, Inc.- Daniel Behr，自2019年8月起担任Ocean Biomedical执行副总裁兼外部创新和学术合作伙伴关系主管。Behr先生曾于2017年7月至2019年7月担任布朗大学工业参与和商业风险办公室执行主任。Behr先生曾担任SLIPS技术公司的首席执行官。
- Daniel Behr,has served as Ocean Biomedical's EVP and Head of External Innovation and Academic Partnerships since August 2019. Mr. Behr previously served as Executive Director of the Brown University Office of Industry Engagement and Commercial Venturing from July 2017 to July 2019. Mr. Behr served as the Chief Executive Officer of SLIPS Technologies, Inc.
- Robert Sweeney
Robert Sweeney，自2021年6月14日起担任Ocean Biomedical的首席会计师。Sweeney先生在金融和税务方面拥有超过35年的经验，专门研究包括财富10强公司和初创公司在内的技术领域。2012年2月至2021年6月，Sweeney先生担任自己的会计和咨询公司RJS Consulting，LLC的管理成员。斯威尼此前曾在多家高科技公司担任首席财务官，包括Flashfoto，Inc。
Robert Sweeney,has served as Ocean Biomedical's Chief Accounting Officer since June 14, 2021. Mr. Sweeney has over 35 years' experience in financial and tax matters, specializing in the technology sector that includes both Fortune 10 companies and start-up companies. Mr. Sweeney was the Managing Member of his own accounting and consulting company, RJS Consulting, LLC, from February 2012 until June 2021. Mr. Sweeney previously served as the Chief Financial Officer of various high technology companies, including Flashfoto, Inc.- Robert Sweeney，自2021年6月14日起担任Ocean Biomedical的首席会计师。Sweeney先生在金融和税务方面拥有超过35年的经验，专门研究包括财富10强公司和初创公司在内的技术领域。2012年2月至2021年6月，Sweeney先生担任自己的会计和咨询公司RJS Consulting，LLC的管理成员。斯威尼此前曾在多家高科技公司担任首席财务官，包括Flashfoto，Inc。
- Robert Sweeney,has served as Ocean Biomedical's Chief Accounting Officer since June 14, 2021. Mr. Sweeney has over 35 years' experience in financial and tax matters, specializing in the technology sector that includes both Fortune 10 companies and start-up companies. Mr. Sweeney was the Managing Member of his own accounting and consulting company, RJS Consulting, LLC, from February 2012 until June 2021. Mr. Sweeney previously served as the Chief Financial Officer of various high technology companies, including Flashfoto, Inc.